Vaxcyte Reports Positive Phase 2 Results For VAX-24 Infant Pneumococcal Vaccine

Vaxcyte

27.50 CHF 3.54%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - Vaxcyte, Inc. (PCVX) Monday reported positive topline results from its Phase 2 study evaluating VAX-24, a 24-valent pneumococcal conjugate vaccine for infants.

The study assessed safety, tolerability, and immunogenicity compared to Pfizer's approved Prevnar 20 vaccine. Based on the data, Vaxcyte has selected the Mid-dose for further development and plans to initiate a Phase 3 infant study, pending additional results in 2026.

VAX-24 was well-tolerated, demonstrated strong immune responses, and met key immunogenicity criteria. Full booster data is expected by late 2025, with broader clinical advancements planned for both adult and infant indications.

Meanwhile, shares of Vaxcyte and other vaccine manufacturers have plummeted following the announcement of Peter Marks' resignation, a key vaccine official at the FDA.

PCVX is currently trading at $32.75 down $36.71 or 52.69 percent on the Nasdaq.